Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548341 | 0.85 | CYP1A2 (0.58) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL1713540 | 0.85 | CYP1A2 (0.58) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL4851530 | 0.84 | KDM4E (0.42) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL20505208 | 0.83 | ALB (0.48) | CYP1A2KDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL27157346 | 0.83 | KDM4E (0.41) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL30047468 | 0.83 | KDM4E (0.41) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL4758562 | 0.83 | AKR1C2 (0.44) | CYP1A2KDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL16122325 | 0.83 | KDM4E (0.50) | CYP1A2KDM4EASPHKDM8CES2 | |
| SCHEMBL14157169 | 0.81 | CASP7 (0.42) | CYP1A2KDM4EASPHKDM8ALDH1A1 | |
| SCHEMBL7495208 | 0.81 | KDM4E (0.40) | CYP1A2KDM4EASPHKDM8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 271 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117839587-A | Synthesis method of polysubstituted 2-hydroxybenzaldehyde | 烟台宁远药业有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | NFLECTION THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12480049-B2 | Compound and liquid crystal composition | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2025-11-25 | — | — | US | disclosed |
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-13 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-14 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-5856490-A | Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity | ALLERGAN (US) | 1999-01-05 | — | — | US | disclosed |
| EP-0882725-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0876330-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0869782-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RAR $g(a)? RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | Vision Pharmaceuticals L.P. (US) | 1998-10-14 | — | — | EP | disclosed |
| EP-0862555-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | Allergan (US) | 1998-09-09 | — | — | EP | disclosed |
| US-5675024-A | RETINOID RECEPTOR AGONISTS | ALLERGAN (US) | 1997-10-07 | — | — | US | disclosed |
| US-5663357-A | COMPOUNDS FOR TREATMENT OF SKIN DISORDERS | ALLERGAN (US) | 1997-09-02 | — | — | US | disclosed |
| WO-1997024116-A2 | METHODS OF TREATMENT WITH COMPOUNDS HAVING RARα RECEPTOR SPECIFIC OR SELECTIVE ACTIVITY | VISION PHARMACEUTICALS L.P. (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997019062-A1 | SUBSTITUTED ARYL OR HETEROARYLAMIDES HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997019052-A1 | ARYL OR HETEROARYL AMIDES OF TETRAHYDRONAPHTHALENE, CHROMAN, THIOCHROMAN AND 1,2,3,4-TETRAHYDROQUINOLINE CARBOXYLIC ACIDS HAVING RETINOID-LIKE BIOLOGICAL ACTIVITY | ALLERGAN (US) | 1997-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | CYP1A2 464/4885KDM4E 2870/4885ASPH 3249/4885 |
| US-12441735-B2 | Nitrogen-containing heterocyclic compound having NRF2 activation effect | KEAP1, NFE2L2, BACH1 | CYP1A2 512/4885KDM4E 3660/4885ASPH 3422/4885 |
| US-20250346574-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | RECQL, H1-5, H1-3 | CYP1A2 2472/4885KDM4E 1694/4885ASPH 2086/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | CYP1A2 3817/4885KDM4E 4319/4885ASPH 2737/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | CYP1A2 2422/4885KDM4E 958/4885ASPH 2418/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | CYP1A2 3971/4885KDM4E 4485/4885ASPH 2688/4885 |
| US-20250387379-A1 | ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS | SUB1, AHR, NCOA3 | CYP1A2 110/4885KDM4E 2358/4885ASPH 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.